These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Management of the cutaneous peripheral T-cell lymphomas: when subtypes matter. Choi MY; Lechowicz MJ Cancer J; 2012; 18(5):439-44. PubMed ID: 23006949 [TBL] [Abstract][Full Text] [Related]
44. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ; J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639 [TBL] [Abstract][Full Text] [Related]
45. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides. Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425 [TBL] [Abstract][Full Text] [Related]
46. Adult T-cell leukemia/lymphoma clinically confused with viral/drug skin eruptions and pathologically misinterpreted as mycosis fungoides/Sézary syndrome. AbdullGaffar B; Abdulrahman S J Cutan Pathol; 2021 Sep; 48(9):1103-1108. PubMed ID: 33354782 [TBL] [Abstract][Full Text] [Related]
47. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480 [TBL] [Abstract][Full Text] [Related]
48. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients. Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617 [TBL] [Abstract][Full Text] [Related]
54. Cyclosporine in the treatment of cutaneous T cell lymphoma. Street ML; Muller SA; Pittelkow MR J Am Acad Dermatol; 1990 Dec; 23(6 Pt 1):1084-9. PubMed ID: 2273106 [TBL] [Abstract][Full Text] [Related]
55. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. Devata S; Wilcox RA Am J Clin Dermatol; 2016 Jun; 17(3):225-37. PubMed ID: 26923912 [TBL] [Abstract][Full Text] [Related]
56. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936 [TBL] [Abstract][Full Text] [Related]
57. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments. Stuver R; Geller S Front Immunol; 2023; 14():1284045. PubMed ID: 37868986 [TBL] [Abstract][Full Text] [Related]